Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI?driven Internet healthcare solutions, announced the launch of Kyinsu®, the world’s first once-weekly basal insulin/GLP-1 RA combination therapy, on its Internet hospital platform, further expanding its collaboration with global healthcare company Novo Nordisk to improve access to innovative diabetes treatments through AI-powered chronic disease management services. China is the first market globally to commercialize Kyinsu®, making Fangzhou one of the product’s key launch partners. Leveraging its AI-enabled chronic disease management ecosystem and nationwide pharmaceutical supply chain, the Company aims to accelerate…